All In Biotech

Drug Trial Radar · NCT06422806

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 365 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

365

Planned (sponsor's estimate)

Start

Sep 11, 2024

Primary completion

Apr 18, 2032

Study completion Apr 18, 2032

Sponsor

Sponsor type
NIH
First posted
May 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.

Conditions

  • Metastatic Dedifferentiated Liposarcoma
  • Metastatic Undifferentiated Pleomorphic Sarcoma
  • Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
  • Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
  • Unresectable Dedifferentiated Liposarcoma
  • Unresectable Undifferentiated Pleomorphic Sarcoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Diagnostic Imaging TestingProcedure

    Undergo standard imaging scans

  • DoxorubicinDrug

    Given IV

  • Echocardiography TestProcedure

    Undergo ECHO

  • Multigated Acquisition ScanProcedure

    Undergo MUGA scan

  • PembrolizumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: From randomization to documented progression (per Response Evaluation Criteria in Solid Tumors version 1.1) or death from any cause without prior progression, up to 5 years

Locations

269 sites in 3 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona · Recruiting

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Recruiting

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Recruiting

  • Kaiser Permanente Dublin

    Dublin, California · Recruiting

  • Kaiser Permanente-Fremont

    Fremont, California · Recruiting

  • Kaiser Permanente Fresno Orchard Plaza

    Fresno, California · Recruiting

  • Kaiser Permanente-Fresno

    Fresno, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • Keck Medicine of USC Koreatown

    Los Angeles, California · Recruiting

  • Los Angeles General Medical Center

    Los Angeles, California · Recruiting

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Kaiser Permanente- Modesto MOB II

    Modesto, California · Recruiting

  • Kaiser Permanente-Modesto

    Modesto, California · Recruiting

  • USC Norris Oncology/Hematology-Newport Beach

    Newport Beach, California · Recruiting

  • Kaiser Permanente-Oakland

    Oakland, California · Recruiting

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California · Recruiting

  • VA Palo Alto Health Care System

    Palo Alto, California · Recruiting

  • Huntington Memorial Hospital

    Pasadena, California · Recruiting

  • Kaiser Permanente-Roseville

    Roseville, California · Recruiting

  • Kaiser Permanente Downtown Commons

    Sacramento, California · Recruiting

  • Kaiser Permanente-South Sacramento

    Sacramento, California · Recruiting

  • Kaiser Permanente-San Francisco

    San Francisco, California · Recruiting

  • UCSF Medical Center-Mission Bay

    San Francisco, California · Recruiting

  • Kaiser Permanente-Santa Teresa-San Jose

    San Jose, California · Recruiting

  • Kaiser Permanente San Leandro

    San Leandro, California · Recruiting

  • Kaiser San Rafael-Gallinas

    San Rafael, California · Recruiting

  • Kaiser Permanente Medical Center - Santa Clara

    Santa Clara, California · Recruiting

  • Kaiser Permanente-Santa Rosa

    Santa Rosa, California · Recruiting

  • Kaiser Permanente-South San Francisco

    South San Francisco, California · Recruiting

  • Kaiser Permanente-Vallejo

    Vallejo, California · Recruiting

  • Kaiser Permanente-Walnut Creek

    Walnut Creek, California · Recruiting

  • UCHealth University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • Poudre Valley Hospital

    Fort Collins, Colorado · Recruiting

  • Cancer Care and Hematology-Fort Collins

    Fort Collins, Colorado · Recruiting

  • UCHealth Greeley Hospital

    Greeley, Colorado · Recruiting

  • Medical Center of the Rockies

    Loveland, Colorado · Recruiting

  • Smilow Cancer Hospital-Derby Care Center

    Derby, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center-Fairfield

    Fairfield, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center at Greenwich

    Greenwich, Connecticut · Recruiting

Showing 40 of 269 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.